Troculeucel

在癌症治疗领域，传统方法如化疗、放疗等虽有一定疗效，但往往伴随着诸多副作用，给患者带来极大的痛苦。近年来，免疫治疗作为一种新兴的治疗手段，逐渐崭露头角，其中NK细胞疗法更是成为了备受瞩目的焦点。NK细胞，作为人体抗击癌细胞和病毒的第一道防线，正以其独特的魅力和巨大的潜力，为癌症患者带来新的希望。 NK细胞：人体免疫的“先锋卫士” NK细胞，全称自然杀伤细胞，主要分布在人体的血液、肝、脾、骨髓等部位。它是一种独特的先天免疫细胞，与T细胞、B细胞等适应性免疫细胞不同，NK细胞无需事先致敏或抗原识别，就能对癌细胞和病原体发起快速而有效的攻击，展现出强大的细胞毒性。这种特性使得NK细胞在癌症免疫治疗和病原体清除方面具有天然的优势，能够满足大规模生产癌症免疫治疗的临床需求，成为人体免疫系统中不可或缺的“先锋卫士”。田志刚院士：NK细胞延长患者生存期的有力见证 2023年，在中国科学技术大学免疫学研究所田志刚院士于第十三届北京消化肿瘤国际高峰论坛暨CGOG2023年会上，以“基于NK细胞的肿瘤免疫治疗”为主题进行了精彩的专题报告。报告中，田志刚院士详细介绍了NK细胞疗法NK010的IIT临床试验情况。 该试验聚焦于预计生存期仅为2 - 6个月的铂耐药晚期卵巢癌患者。在众多患者中，有一位患者的经历尤为引人注目。这位患者于2014年被确诊为晚期卵巢癌，此前接受了手术和化疗等多种治疗手段，然而到了2018年，病情还是出现了进展。无奈之下，患者入组了NK细胞治疗的临床研究。入组时，其直肠右前方病灶大小为1.9cm，右侧结肠旁沟病灶大小为1.3cm。经过NK细胞治疗后，奇迹发生了，直肠右前方病灶竟然完全消失，右侧结肠旁沟病灶也缩小至0.4cm。截至2020年9月，这位患者已经存活至少40个月，远远超出了最初的预计生存期。这一案例充分证明了NK细胞疗法在延长晚期卵巢癌患者生存期方面的显著效果，为众多绝望中的患者带来了新的生机。 多案例见证：NK细胞疗法的卓越成效肉瘤患者的“重生”之路：SNK01显神威 SNK01是一种具有创新性的NK细胞产品。2016年12月，一位西班牙裔男性被诊断出患有转移性促结缔组织增生性小圆细胞肿瘤，这是一种极为罕见且恶性程度较高的肿瘤。此后，该患者先后接受了多种化疗方案以及曲贝替定和帕博利珠单抗等治疗，但病情依然在2019年10月出现了进展。 就在患者陷入绝境之时，2019年11月，他开始接受SNK01治疗。经过5次治疗后，患者的病情逐渐稳定下来。治疗一年后，令人惊喜的是，患者的肿瘤缩小了47%，达到了部分缓解（PR）的标准。之后，患者又接受了减瘤手术以及放化疗，并在2个月之后再次接受SNK01联合帕博利珠单抗治疗。截至2022年1月，该患者仍旧持续缓解中，没有出现任何疾病迹象，仿佛获得了“重生”。这一案例充分展示了SNK01在肉瘤治疗中的巨大潜力，为肉瘤患者带来了新的治疗选择和希望。GDA - 201：淋巴瘤患者的“消退利器” GDA - 201是一种NK细胞疗法候选药物，在针对B细胞淋巴瘤患者的1/2期研究试验中，取得了令人瞩目的成果。共有7例患者参与试验，其中3例患者达到了完全缓解（CR），这意味着他们体内的肿瘤完全消失；2例患者达到了部分缓解（PR），肿瘤明显缩小；还有2例患者病情稳定（SD），肿瘤没有进一步恶化。 以患者108为例，其身上的101个目标病灶在接受GDA - 201治疗后完全消退；患者102在给药后肿瘤也出现了明显的消退。这些真实的数据和案例，充分证明了GDA - 201在淋巴瘤治疗中的有效性和安全性，为淋巴瘤患者带来了新的曙光。 NK细胞疗法联合曲妥珠单抗：HER2阳性实体瘤的新希望 2020年9月，《CLINICAL CANCER RESEARCH》杂志发表了一项关于NK细胞疗法联合曲妥珠单抗在HER2阳性实体瘤患者中的I期临床疗效研究。该研究共纳入了31例患者，其中30例为乳腺癌患者，1例为胃癌患者。 研究结果显示，1例患者实现了部分缓解（PR），16例患者病情稳定（SD）。其中，实现部分缓解的患者是一位激素受体阳性（HR +）、HER2阳性的转移性乳腺癌患者，此前已经接受过多种化疗、抗HER2和激素治疗，但病情仍然进展。然而，在接受NK输注两个周期后，患者竟然实现了部分缓解（PR），这无疑是一个令人振奋的消息。这一研究结果表明，NK细胞疗法联合曲妥珠单抗在HER2阳性实体瘤患者中具有初步的抗肿瘤疗效，为这类患者的治疗提供了新的思路和方法。联合治疗：癌症治疗的未来趋势 从上述多个案例中我们可以看出，NK细胞疗法联合其他治疗方法相较于传统的化疗和放疗，具有更好的疗效。传统的化疗和放疗在杀死癌细胞的同时，也会对正常细胞造成较大的损伤，导致患者出现一系列严重的副作用，如恶心、呕吐、脱发、免疫力下降等，严重影响患者的生活质量。 而NK细胞疗法联合治疗则具有独特的优势。一方面，NK细胞能够直接识别并杀伤癌细胞，增强机体的免疫功能；另一方面，联合其他治疗方法如靶向治疗、免疫检查点抑制剂等，可以发挥协同作用，从不同角度攻击癌细胞，提高治疗效果。例如，NK细胞疗法联合曲妥珠单抗，曲妥珠单抗可以特异性地结合HER2阳性癌细胞表面的HER2受体，阻断癌细胞的生长信号传导，同时增强NK细胞对癌细胞的识别和杀伤能力，从而达到更好的治疗效果。 我国NK细胞临床研究：蓬勃发展，未来可期 目前，NK细胞疗法已在乳腺癌、肺癌、结直肠癌、胃癌、肝细胞癌以及卵巢癌等众多实体瘤的临床试验中取得了重大进展。我国关于NK细胞的临床研究也在如火如荼地进行中。众多科研机构和医疗机构纷纷投入大量的人力、物力和财力，开展NK细胞疗法的基础研究和临床试验，不断探索NK细胞疗法在癌症治疗中的最佳应用方案。 随着研究的不断深入和技术的不断进步，我们有理由相信，NK细胞疗法将会取得更大的突破。未来，NK细胞疗法有望成为癌症治疗的重要手段之一，为更多的肿瘤患者带来福音，让他们重新燃起生命的希望。 文章来源于网络，转载此文是出于传递更多信息之目的。若有来源标注错误或侵犯了您的合法权益，请作者持权属证明与本网联系,  我们将及时更正、删除，  谢谢。

SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea. NKGen Presentation Details : Title : Use of Troculeucel (Cryopreserved Enhanced Autologous NK Cell Therapy) for Neurodegenerative Diseases Track: Cell & Gene Therapy Innovations and R&D Collaboration Date & Time: Friday, July 10, 2026, at 13:40– 14:00 KST (12:40–1:00 AM ET) Dr. Song’s presentation will provide an overview of troculeucel, the Company’s lead investigational program currently being evaluated in a Phase 2 clinical trial for Alzheimer’s disease, and discuss NKGen’s ongoing efforts to advance its innovative NK cell therapy platform for additional neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s disease. Dr. Song will further discuss the regulatory environment in China, including certain frameworks and policies in select free-trade zones that may support the development and potential commercialization of therapeutics, including those in U.S. FDA Phase 2 clinical trials, and may be relevant to potential collaborations with Chinese pharmaceutical companies and contract development and manufacturing Organizations (CDMOs). The BIOCHINA Global Forum is a leading international biotechnology partnering and innovation conference which serves as a platform for scientific exchange, strategic collaboration, and cross-border business development within the global life sciences sector. NKGen’s participation reflects the Company’s commitment to engaging with global biotechnology leaders and exploring opportunities to expand its strategic network across development, manufacturing, and commercialization. The conference provides a valuable forum for discussions with potential partners that may support the future advancement and global development of the Company’s pipeline programs. A copy of the presentation will be made available on the Company’s website under the Scientific Publications section once the event has concluded. Additionally, previously disclosed scientific data on troculeucel for neurodegenerative disease can be accessed on the same page. For the latest updates on our clinical trials and regulatory announcements, please visit the Company’s News page. About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit . Forward-Looking Statements Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s anticipated timing and content of its filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public disclosures; the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. Additional risks include uncertainties related to the Company’s acquisition of a majority interest in NKGen Biotech Korea Co., Ltd., including risks regarding the future performance of NKGen Biotech Korea Co., Ltd.’s business, the Company’s ability to successfully integrate NKGen Biotech Korea Co., Ltd.’s operations, personnel, and technologies, potential challenges in realizing expected synergies and cost savings, and risks that the Company may not achieve the anticipated strategic, financial, or operational benefits of the acquisition on the expected timeline or at all. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the SEC’s website at and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP) SVP, Corporate Affairs 949-396-6830 dchua@NKGenbiotech.com External Contacts: Kevin Gardner Managing Director LifeSci Advisors, LLC kgardner@lifesciadvisors.com